Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Non Operating Income came in at $3.7 million in Q1 2026, up 131.89% YoY from $1.6 million in Q1 2025, and up 129.47% on a QoQ basis from -$12.5 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Non Operating Income data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Non Operating Income rose 131.89% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.4 million (up 9.94% YoY) and the FY2025 annual result came in at -$46.8 million, down 311.36% from the prior year.
- Non Operating Income improved to $3.7 million in Q1 2026, from -$12.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.7 million in Q1 2026 to a low of -$13.7 million in Q4 2024.
- A 5-year average of -$3.7 million and a median of -$680000.0 in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 418.24% in 2024, down 1505.3% in 2024.
- Tracing ARWR's Non Operating Income over 5 years: stood at $340000.0 in 2022, then tumbled by 730.59% to -$2.1 million in 2023, then slumped by 539.13% to -$13.7 million in 2024, then grew by 8.5% to -$12.5 million in 2025, then surged by 129.47% to $3.7 million in 2026.
- The last three Non Operating Income figures came in at $3.7 million (Q1 2026), -$12.5 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.81 Mn |
| Mar 31, 2026 | 3.70 Mn |
| Dec 31, 2025 | -12.54 Mn |
| Sep 30, 2025 | -7.99 Mn |
| Jun 30, 2025 | -13.54 Mn |
| Mar 31, 2025 | -11.59 Mn |
| Dec 31, 2024 | -13.70 Mn |
| Sep 30, 2024 | -10.60 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | -805,000.00 |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | -660,000.00 |
| Jun 30, 2023 | -680,000.00 |
| Mar 31, 2023 | -489,000.00 |
| Dec 31, 2022 | 340,000.00 |
| Sep 30, 2022 | 1.67 Mn |
| Jun 30, 2022 | 863,000.00 |
| Mar 31, 2022 | 2.81 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Sep 30, 2021 | 1.51 Mn |